Nivolumab – March 2026

Solution for subcutaneous injection 600 mg in 5 mL,

  • Brand names:
    • Opdivo®
  • Pharmaceutical Company:
    • BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD
  • Condition/Indication: Malignant melanoma Non-Small Cell Lung Cancer (NSCLC). Renal Cell Carcinoma (RCC). Squamous Cell Carcinoma of the Head and Neck (SCCHN). Urothelial Carcinoma (UC). Oesophageal / Gastro-oesophageal cancers(OC/GC).
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026